AI-generated analysis. Always verify with the original filing.
Edesa Biotech, Inc. reported financial results for the three months ended December 31, 2025, with total operating expenses of $2.3 million, net loss of $2.2 million or $0.28 per common share, cash and cash equivalents of $12.1 million, and working capital of $12.0 million. The company progressed EB06 manufacturing for a Phase 2 vitiligo study starting midyear 2026 and is evaluating paridiprubart Phase 3 data.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. On February 13, 2026, Edesa Biotech, Inc. (the “Company”) issued a press release announcing its financial resul
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Edesa Biotech, Inc. dated February 13, 2026. 104 Cover Pa
| Metric | Value | Basis |
|---|---|---|
| Total Operating Expenses | $2.30 | GAAP |
| Research and Development Expenses | $1.10 | GAAP |
| General and Administrative Expenses | $1.20 | GAAP |
| Net Loss | $2.20 | GAAP |
| Loss per Common Share | $0.28 | GAAP |